ZEVRA THERAPEUTICS, INC.
ZVRANasdaq
$12.77
↑ +0.1%Jul 17 close · end-of-day
Price
1Y↑ +3.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$769.1M
Enterprise Value
$568.5M
P/E
6.4
P/S
6.3
P/B
3.7
EV/EBITDA
—
PEG
—
FCF Yield
1.6%
Dividend Yield
—
Revenue (TTM)
$122.3M
Net Income (TTM)
$124.2M
Free Cash Flow (TTM)
$12.0M
Gross Margin
—
Operating Margin
-4.4%
Net Margin
101.6%
ROE
60.4%
ROIC
-97.5%
Debt / Equity
0.0
Net Cash
$200.6M
Return 1Y
+0.9%
Company profile
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. Its product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH)
- CEO
- Travis C. Mickle
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 20
- Headquarters
- Florida
- Website
- kempharm.com
Management & directors
- Thompson RahsaanChief Legal & Compliance
- Mcfarlane Neil F.President and CEO
- Sangiovanni Timothy J.SVP, Finance & Corp Controller
- Schafer JoshuaCCO
- Quartel Adrian WChief Medical Officer
Roles derived from SEC Form 4 filings.
Earnings
ZVRA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$36.2M↑ +77.5%
Diluted EPS$0.60↓ -1100.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $13.3M | $28.6M | $10.2M | $27.5M | $23.6M | $106.5M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$5.6M | $7.7M | -$42.6M | -$49.6M | -$87.0M | -$62.9M |
| Net income | -$12.8M | -$8.6M | -$26.8M | -$46.0M | -$105.5M | $83.2M |
| Diluted EPS | -$3.21 | -$2.11 | — | — | -$2.28 | $1.35 |
| Operating cash flow | -$1.9M | $10.4M | -$18.7M | -$33.5M | -$69.7M | -$1.6M |
| Free cash flow | -$2.0M | $10.3M | -$18.8M | -$33.8M | -$69.7M | -$2.4M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -42.2% | 27.0% | -418.9% | -180.6% | -368.5% | -59.1% |
| Net margin | -96.0% | -29.9% | -263.5% | -167.7% | -446.9% | 78.2% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.4M | $3.7M | $12.0M | $20.4M | $25.9M | $26.1M | $34.1M | $36.2M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$23.8M | -$27.3M | -$15.4M | -$5.4M | -$71.0M | $4.1M | $9.3M | $52.1M |
| Net income | -$19.9M | -$33.2M | -$35.7M | -$3.1M | $74.7M | -$544,000.00 | $12.2M | $37.9M |
| Diluted EPS | -$0.48 | -$0.69 | — | -$0.06 | $1.21 | -$0.01 | $0.21 | $0.60 |
| Operating cash flow | -$19.1M | -$18.1M | -$16.3M | -$8.2M | -$3.6M | $4.7M | $5.5M | $6.1M |
| Free cash flow | -$19.1M | -$18.1M | -$16.3M | -$8.3M | -$3.8M | $4.2M | $5.5M | $6.1M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -534.8% | -739.0% | -128.0% | -26.3% | -274.5% | 15.9% | 27.3% | 144.0% |
| Net margin | -447.9% | -899.2% | -296.8% | -15.2% | 288.7% | -2.1% | 35.6% | 104.6% |
Company news
Jun 9, 2026
Jun 8, 2026
- 42d agoZVRA Stock ‘Way Undervalued’? Analyst Sees 117% Upside After Patent Extends Exclusivity Till 2041 For Sole Approved Drugstocktwits.com
- 42d agoZevra Therapeutics extends MIPLYFFA exclusivity to 2041proactiveinvestors.com
- 42d agoZevra Therapeutics Announces Orange Book Listing of U.S. Patent Strengthening Exclusivity for MIPLYFFAfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-22 | Thompson Rahsaan· Chief Legal & Compliance | Sale | 34,557 | $12.68 | $438,303.71 | filing |
| 2026-06-21 | Thompson Rahsaan· Chief Legal & Compliance | Option exercise | 66,667 | — | — | filing |
| 2026-05-11 | Thompson Rahsaan· Chief Legal & Compliance | Sale | 1,794 | $11.30 | $20,272.20 | filing |
| 2026-03-24 | Bode John B | Option exercise | 39,200 | $4.97 | $194,824.00 | filing |
| 2026-03-24 | Bode John B | Option exercise | 39,200 | $4.89 | $191,688.00 | filing |
| 2026-02-09 | McFarlane Neil F.· President and CEO | Sale | 14,625 | $8.56 | $125,185.61 | filing |
| 2026-02-07 | McFarlane Neil F.· President and CEO | Option exercise | 37,500 | — | — | filing |
| 2026-02-03 | Schafer Joshua· CCO | Sale | 10,500 | $9.19 | $96,500.25 | filing |
| 2026-02-03 | Sangiovanni Timothy J.· SVP, Finance & Corp Controller | Sale | 3,000 | $9.18 | $27,548.10 | filing |
| 2026-02-02 | McFarlane Neil F.· President and CEO | Sale | 91,000 | $9.38 | $853,425.30 | filing |
| 2026-01-31 | Schafer Joshua· CCO | Option exercise | 35,334 | — | — | filing |
| 2026-01-31 | McFarlane Neil F.· President and CEO | Option exercise | 233,334 | — | — | filing |
| 2026-01-31 | Sangiovanni Timothy J.· SVP, Finance & Corp Controller | Option exercise | 11,666 | — | — | filing |
| 2026-01-30 | Quartel Adrian W· Chief Medical Officer | Sale | 4,533 | $8.83 | $40,035.91 | filing |
| 2026-01-30 | Thompson Rahsaan· Chief Legal & Compliance | Sale | 4,080 | $8.83 | $36,009.67 | filing |
| 2026-01-30 | Schafer Joshua· CCO | Sale | 3,375 | $8.83 | $29,800.24 | filing |
| 2026-01-30 | Sangiovanni Timothy J.· SVP, Finance & Corp Controller | Sale | 1,750 | $8.82 | $15,442.00 | filing |
| 2026-01-30 | Sangiovanni Timothy J.· SVP, Finance & Corp Controller | Option exercise | 6,333 | — | — | filing |
| 2026-01-30 | Thompson Rahsaan· Chief Legal & Compliance | Option exercise | 11,333 | — | — | filing |
| 2026-01-30 | Quartel Adrian W· Chief Medical Officer | Option exercise | 11,333 | — | — | filing |
| 2026-01-30 | Schafer Joshua· CCO | Option exercise | 11,333 | — | — | filing |
| 2025-12-31 | Clifton R. LaDuane | Tax withholding | 48,513 | $8.96 | $434,676.48 | filing |
| 2025-12-31 | Clifton R. LaDuane | Option exercise | 140,667 | $0.00 | $0.00 | filing |
| 2025-10-10 | McFarlane Neil F.· President and CEO | Sale | 19,500 | $10.82 | $210,908.10 | filing |
| 2025-10-10 | McFarlane Neil F.· President and CEO | Option exercise | 50,000 | — | — | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.